Browse All

Current Filters

CLEAR FILTER x

TITLE

Real-world Outcomes of Nusinersen or Onasemnogene Abeparvovec (OA) Monotherapy, or Switching to OA from Nusinersen in SMA Patients Aged =6 Months

Author:Dabbous, Omar   Yang, Min   Georgieva, Mihaela   Toro, Walter   LaMarca, Nicole   Patel, Anish   Anderson, Annika   Akbarnejad, Hanane   Reyna, Sandra P.   

Session Name:P7: Child Neurology and Developmental Neurology: Spinomuscular Atrophy/Muscular Dystrophies  

Topic:Child Neurology and Developmental Neurology  

Program Number:P7.001  

Author Institution:Novartis Gene Therapies, Inc., Bannockburn, IL  Analysis Group, Inc., Boston, MA  Analysis Group, Inc., New York, NY